T-DM1 Shows Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer
A single-center study of 21 patients found that trastuzumab emtansine produced no responses and a median progression-free survival of 2.20 ...
A single-center study of 21 patients found that trastuzumab emtansine produced no responses and a median progression-free survival of 2.20 ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.